JNJ Eyes $100B Sales Milestone: Time to Buy?

Johnson & Johnson reported third-quarter 2026 earnings on October 13, with operational revenue growing 6% and management raising its full-year sales outlook. The healthcare giant is now on track to exceed $100 billion in annual revenue for the first time in its 140-year history, a milestone driven primarily by its Innovative Medicine division.

The pharmaceutical unit posted 7.9% operational growth, led by cancer treatments and expanding market share for Tremfya, an injectable therapy for inflammatory diseases. CEO Joaquin Duato highlighted the quarter's momentum, noting that sales exceeded $25 billion and that the company remains on pace to meet its guidance.

MedTech, the company's medical device segment, grew just 2.5% operationally, weighed down by disruptions in the Middle East, China's volume-based procurement program, and slower-than-expected adoption of Abiomed heart pumps. Management acknowledged the shortfall and outlined plans to restore double-digit growth through new product rollouts, including the OTTAVA soft-tissue robotic surgery system.

On portfolio strategy, JNJ clarified that its double-digit growth targets will rely on internal investments rather than large acquisitions. The company is leaning toward a tax-free spinoff of DePuy Synthes, its orthopedics subsidiary, by mid-2027, a move CFO Joseph Wolk said would create the most long-term value for shareholders.

Looking ahead, management expressed confidence in finishing 2026 strong and delivering an even better 2027, citing high-margin oncology treatments, surgical device rollouts, and upcoming regulatory catalysts like VARIPULSE Pro, an electrophysiology catheter.

Crossing $100 billion in annual revenue is more than a symbolic milestone. It signals that JNJ's core pharmaceutical business is firing on all cylinders, generating the cash flow needed to fund its dividend, absorb legal costs, and invest in future growth. For long-term investors, that kind of scale and consistency is a rare commodity in healthcare.

The MedTech slowdown is a near-term concern, but it appears largely tied to external factors like China's procurement policies and Middle East disruptions rather than a loss of competitive edge. If management can execute on its product launches, particularly OTTAVA and VARIPULSE Pro, the segment could return to double-digit growth and become a more meaningful earnings contributor.

The potential spinoff of DePuy Synthes is a classic value-unlocking move. By separating a slower-growth orthopedics business, JNJ can sharpen its focus on higher-margin pharmaceuticals and innovative medical devices. Spinoffs often create shareholder value by allowing each entity to pursue its own strategy and attract a more targeted investor base.

However, risks remain. JNJ continues to face legal overhangs, including talc litigation, and the MedTech recovery is not guaranteed. The company's ability to hit its double-digit growth target by the end of the decade depends on successful execution across multiple fronts, from drug approvals to robotic surgery adoption.

For investors, the key takeaway is that JNJ is evolving. It is not just a defensive dividend stock anymore; it is a company actively reshaping its portfolio to drive faster growth. That could mean a higher earnings multiple over time, but only if the spinoff and product launches deliver as promised.